Merck & Co., Inc. (MRK) EV/EBITDA Ratio: 19.83x
Is Merck & Co., Inc.’s EV/EBITDA ratio high or low?
Merck & Co., Inc.'s EV/EBITDA ratio of 19.83x is 10% above its 5-year average of 18.02x, near the low end of its 5-year range (8.14x–53.05x).
As of Thursday, June 11, 2026. 77.30% above its 12-month average of 11.18x.
MRK EV/EBITDA Ratio Chart
MRK Average EV/EBITDA Ratio Chart
MRK Current vs Average EV/EBITDA Ratio Chart
MRK EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
19.83x
EV/EBITDA RATIO AVG TTM
11.18x
EV/EBITDA RATIO AVG 3Y
19.68x
EV/EBITDA RATIO AVG 5Y
18.02x
EV/EBITDA RATIO AVG 10Y
16.62x
EV/EBITDA RATIO AVG 15Y
14.27x
EV/EBITDA RATIO AVG 20Y
13.13x
CURRENT VS TTM AVG
+77.30%
CURRENT VS 3Y AVG
+0.74%
CURRENT VS 5Y AVG
+10.03%
CURRENT VS 10Y AVG
+19.31%
CURRENT VS 15Y AVG
+38.98%
CURRENT VS 20Y AVG
+51.03%
MRK Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | $298.23B | 19.83x | 11.18x | 19.68x | 18.02x |
| UnitedHealth Group Incorporated (UNH) | $369.16B | 18.27x | 11.83x | 15.00x | 15.99x |
| AbbVie Inc. (ABBV) | $399.86B | 27.47x | 30.40x | 23.53x | 19.98x |
| Amgen Inc. (AMGN) | $188.37B | 14.71x | 13.70x | 14.35x | 14.05x |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 19.44x | 19.75x | 20.47x | 20.32x |
| Gilead Sciences, Inc. (GILD) | $156.35B | 12.52x | 14.17x | 17.98x | 15.97x |
| Abbott Laboratories (ABT) | $155.75B | 17.53x | 18.77x | 19.31x | 18.59x |
| Pfizer Inc. (PFE) | $149.61B | 12.74x | 10.53x | 15.94x | 13.74x |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 35.49x | 47.48x | 54.45x | 52.43x |
| CVS Health Corporation (CVS) | $126.70B | 17.44x | 14.88x | 11.86x | 12.00x |
EV/EBITDA vs. its own history
At 19.8, EV/EBITDA is richer than usual, sitting higher than 92% of its 20-year history.
20-year low
4.0
median
12.7
20-year high
53.0
Merck & Co., Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Merck & Co., Inc. (MRK)?
- The EV/EBITDA ratio for MRK stock is 19.83x.
- Is Merck & Co., Inc.'s EV/EBITDA ratio high or low?
- Merck & Co., Inc.'s EV/EBITDA ratio of 19.83x is 10% above its 5-year average of 18.02x, near the low end of its 5-year range (8.14x–53.05x).
- What is the TTM average EV/EBITDA ratio for Merck & Co., Inc. (MRK)?
- The TTM average EV/EBITDA ratio for MRK stock is 11.18x.
- What is the 3Y average EV/EBITDA ratio for Merck & Co., Inc. (MRK)?
- The 3Y average EV/EBITDA ratio for MRK stock is 19.68x.
- What is the 5Y average EV/EBITDA ratio for Merck & Co., Inc. (MRK)?
- The 5Y average EV/EBITDA ratio for MRK stock is 18.02x.
- What is the 10Y average EV/EBITDA ratio for Merck & Co., Inc. (MRK)?
- The 10Y average EV/EBITDA ratio for MRK stock is 16.62x.
- What is the 15Y average EV/EBITDA ratio for Merck & Co., Inc. (MRK)?
- The 15Y average EV/EBITDA ratio for MRK stock is 14.27x.
- What is the 20Y average EV/EBITDA ratio for Merck & Co., Inc. (MRK)?
- The 20Y average EV/EBITDA ratio for MRK stock is 13.13x.
Merck & Co., Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-11 | 19.83x |
| 2026-06-10 | 19.59x |
| 2026-06-09 | 19.66x |
| 2026-06-08 | 19.65x |
| 2026-06-05 | 19.83x |
| 2026-06-04 | 19.75x |
| 2026-06-03 | 18.96x |
| 2026-06-02 | 19.09x |
| 2026-06-01 | 19.02x |
| 2026-05-29 | 19.53x |
| 2026-05-28 | 19.70x |
| 2026-05-27 | 19.75x |
| 2026-05-26 | 19.68x |
| 2026-05-22 | 20.06x |
| 2026-05-21 | 19.13x |
| 2026-05-20 | 18.71x |
| 2026-05-19 | 18.89x |
| 2026-05-18 | 18.65x |
| 2026-05-15 | 18.48x |
| 2026-05-14 | 18.77x |
| 2026-05-13 | 18.78x |
| 2026-05-12 | 18.62x |
| 2026-05-11 | 18.47x |
| 2026-05-08 | 18.48x |
| 2026-05-07 | 18.61x |
| 2026-05-06 | 18.79x |
| 2026-05-05 | 18.73x |
| 2026-05-04 | 18.73x |
| 2026-05-01 | 11.20x |
| 2026-04-30 | 10.94x |
| 2026-04-29 | 11.10x |
| 2026-04-28 | 11.02x |
| 2026-04-27 | 11.03x |
| 2026-04-24 | 11.18x |
| 2026-04-23 | 11.42x |
| 2026-04-22 | 11.27x |
| 2026-04-21 | 11.24x |
| 2026-04-20 | 11.64x |
| 2026-04-17 | 11.82x |
| 2026-04-16 | 11.50x |
| 2026-04-15 | 11.71x |
| 2026-04-14 | 11.89x |
| 2026-04-13 | 11.91x |
| 2026-04-10 | 12.02x |
| 2026-04-09 | 12.14x |
| 2026-04-08 | 12.18x |
| 2026-04-07 | 11.83x |
| 2026-04-06 | 11.97x |
| 2026-04-02 | 11.98x |
| 2026-04-01 | 11.97x |
| 2026-03-31 | 11.92x |
| 2026-03-30 | 11.73x |
| 2026-03-27 | 11.87x |
| 2026-03-26 | 11.80x |
| 2026-03-25 | 11.84x |
| 2026-03-24 | 11.58x |
| 2026-03-23 | 11.52x |
| 2026-03-20 | 11.38x |
| 2026-03-19 | 11.38x |
| 2026-03-18 | 11.41x |
| 2026-03-17 | 11.53x |
| 2026-03-16 | 11.49x |
| 2026-03-13 | 11.51x |
| 2026-03-12 | 11.54x |
| 2026-03-11 | 11.56x |
| 2026-03-10 | 11.64x |
| 2026-03-09 | 11.64x |
| 2026-03-06 | 11.53x |
| 2026-03-05 | 11.55x |
| 2026-03-04 | 11.92x |
| 2026-03-03 | 11.88x |
| 2026-03-02 | 12.02x |
| 2026-02-27 | 12.24x |
| 2026-02-26 | 11.84x |
| 2026-02-25 | 12.12x |
| 2026-02-24 | 12.25x |
| 2026-02-23 | 12.09x |
| 2026-02-20 | 11.94x |
| 2026-02-19 | 11.91x |
| 2026-02-18 | 11.89x |
| 2026-02-17 | 11.88x |
| 2026-02-13 | 11.87x |
| 2026-02-12 | 11.67x |
| 2026-02-11 | 11.67x |
| 2026-02-10 | 11.48x |
| 2026-02-09 | 11.52x |
| 2026-02-06 | 11.91x |
| 2026-02-05 | 11.72x |
| 2026-02-04 | 11.59x |
| 2026-02-03 | 11.36x |
| 2026-02-02 | 11.14x |
| 2026-01-30 | 10.85x |
| 2026-01-29 | 10.68x |
| 2026-01-28 | 10.55x |
| 2026-01-27 | 10.64x |
| 2026-01-26 | 10.59x |
| 2026-01-23 | 10.67x |
| 2026-01-22 | 10.76x |
| 2026-01-21 | 10.93x |
| 2026-01-20 | 10.78x |
| 2026-01-16 | 10.72x |
| 2026-01-15 | 10.92x |
| 2026-01-14 | 10.92x |
| 2026-01-13 | 10.67x |
| 2026-01-12 | 10.76x |
| 2026-01-09 | 10.88x |
| 2026-01-08 | 10.92x |
| 2026-01-07 | 10.70x |
| 2026-01-06 | 10.73x |
| 2026-01-05 | 10.60x |
| 2026-01-02 | 10.51x |
| 2025-12-31 | 10.40x |
| 2025-12-30 | 10.47x |
| 2025-12-29 | 10.52x |
| 2025-12-26 | 10.54x |
| 2025-12-24 | 10.51x |
| 2025-12-23 | 10.38x |
| 2025-12-22 | 10.35x |
| 2025-12-19 | 10.02x |
| 2025-12-18 | 9.99x |
| 2025-12-17 | 9.85x |
| 2025-12-16 | 9.77x |
| 2025-12-15 | 9.95x |
| 2025-12-12 | 9.95x |
| 2025-12-11 | 9.83x |
| 2025-12-10 | 9.71x |
| 2025-12-09 | 9.64x |
| 2025-12-08 | 9.83x |
| 2025-12-05 | 9.90x |
| 2025-12-04 | 10.00x |
| 2025-12-03 | 10.13x |
| 2025-12-02 | 10.02x |
| 2025-12-01 | 10.09x |
| 2025-11-28 | 10.36x |
| 2025-11-26 | 10.34x |
| 2025-11-25 | 10.44x |
| 2025-11-24 | 9.96x |
| 2025-11-21 | 9.72x |
| 2025-11-20 | 9.47x |
| 2025-11-19 | 9.47x |
| 2025-11-18 | 9.60x |
| 2025-11-17 | 9.27x |
| 2025-11-14 | 9.28x |
| 2025-11-13 | 9.28x |
| 2025-11-12 | 9.15x |
| 2025-11-11 | 9.10x |
| 2025-11-10 | 8.72x |
| 2025-11-07 | 8.68x |
| 2025-11-06 | 8.63x |
| 2025-11-05 | 8.51x |
| 2025-11-04 | 9.53x |
| 2025-11-03 | 9.40x |
| 2025-10-31 | 9.75x |
| 2025-10-30 | 9.78x |
| 2025-10-29 | 9.81x |
| 2025-10-28 | 9.85x |
| 2025-10-27 | 9.95x |
| 2025-10-24 | 9.90x |
| 2025-10-23 | 9.87x |
| 2025-10-22 | 9.91x |
| 2025-10-21 | 9.91x |
| 2025-10-20 | 9.78x |
| 2025-10-17 | 9.63x |
| 2025-10-16 | 9.54x |
| 2025-10-15 | 9.56x |
| 2025-10-14 | 9.62x |
| 2025-10-13 | 9.72x |
| 2025-10-10 | 9.75x |
| 2025-10-09 | 9.90x |
| 2025-10-08 | 9.79x |
| 2025-10-07 | 9.91x |
| 2025-10-06 | 10.03x |
| 2025-10-03 | 10.07x |
| 2025-10-02 | 10.10x |
| 2025-10-01 | 10.17x |
| 2025-09-30 | 9.54x |
| 2025-09-29 | 9.00x |
| 2025-09-26 | 9.00x |
| 2025-09-25 | 8.90x |
| 2025-09-24 | 9.11x |
| 2025-09-23 | 9.14x |
| 2025-09-22 | 9.19x |
| 2025-09-19 | 9.30x |
| 2025-09-18 | 9.30x |
| 2025-09-17 | 9.26x |
| 2025-09-16 | 9.26x |
| 2025-09-15 | 9.25x |
| 2025-09-12 | 9.43x |
| 2025-09-11 | 9.66x |
| 2025-09-10 | 9.55x |
| 2025-09-09 | 9.61x |
| 2025-09-08 | 9.56x |
| 2025-09-05 | 9.62x |
| 2025-09-04 | 9.55x |
| 2025-09-03 | 9.57x |
| 2025-09-02 | 9.70x |
| 2025-08-29 | 9.56x |
| 2025-08-28 | 9.47x |
| 2025-08-27 | 9.56x |
| 2025-08-26 | 9.65x |
| 2025-08-25 | 9.68x |
| 2025-08-22 | 9.89x |
| 2025-08-21 | 9.76x |
| 2025-08-20 | 9.62x |
| 2025-08-19 | 9.64x |
| 2025-08-18 | 9.57x |
| 2025-08-15 | 9.57x |
| 2025-08-14 | 9.42x |
| 2025-08-13 | 9.42x |
| 2025-08-12 | 9.18x |
| 2025-08-11 | 9.15x |
| 2025-08-08 | 9.22x |
| 2025-08-07 | 9.18x |
| 2025-08-06 | 9.09x |
| 2025-08-05 | 9.23x |
| 2025-08-04 | 8.76x |
| 2025-08-01 | 8.71x |
| 2025-07-31 | 8.59x |
| 2025-07-30 | 8.94x |
| 2025-07-29 | 9.03x |
| 2025-07-28 | 9.17x |
| 2025-07-25 | 9.23x |
| 2025-07-24 | 9.17x |
| 2025-07-23 | 9.16x |
| 2025-07-22 | 8.93x |
| 2025-07-21 | 8.71x |
| 2025-07-18 | 8.77x |
| 2025-07-17 | 8.92x |
| 2025-07-16 | 9.01x |
| 2025-07-15 | 8.92x |
| 2025-07-14 | 9.13x |
| 2025-07-11 | 9.10x |
| 2025-07-10 | 9.16x |
| 2025-07-09 | 9.13x |
| 2025-07-08 | 8.91x |
| 2025-07-07 | 8.86x |
| 2025-07-03 | 8.86x |
| 2025-07-02 | 9.01x |
| 2025-07-01 | 8.95x |
| 2025-06-30 | 8.69x |
| 2025-06-27 | 8.69x |
| 2025-06-26 | 8.66x |
| 2025-06-25 | 8.74x |
| 2025-06-24 | 8.81x |
| 2025-06-23 | 8.79x |
| 2025-06-20 | 8.68x |
| 2025-06-18 | 8.71x |
| 2025-06-17 | 8.61x |
| 2025-06-16 | 8.87x |
| 2025-06-13 | 8.94x |
| 2025-06-12 | 8.95x |
| 2025-06-11 | 8.81x |
| 2025-06-10 | 8.91x |
| 2025-06-09 | 8.71x |
| 2025-06-06 | 8.67x |
| 2025-06-05 | 8.54x |
| 2025-06-04 | 8.61x |
| 2025-06-03 | 8.50x |
| 2025-06-02 | 8.41x |
| 2025-05-30 | 8.47x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis